Effects of CYP2C9 and COX-2 gene polymorphisms on the clinical efficacy of non steroidal anti-inflammatory drugs in the treatment of ankylosing spondylitis
Effects of CYP2C9 and COX-2 gene polymorphisms on the clinical efficacy of non steroidal anti-inflammatory drugs in the treatment of ankylosing spondylitis
Objective To investigate the effects of cytochrome P450 isozyme 2C9(CYP2C9)and cyclooxygenase-2(COX-2)gene polymorphisms on the clinical efficacy of non steroidal anti-inflammatory drugs in the treatment of ankylosing spondylitis(AS).Methods 117 patients with AS treated in our hospital from January 2020 to June 2021 were selected as the observation group.Ac-cording to the principle of the same gender and age±1 year,117 subjects who underwent physical examination in our hospital in the same period were selected as the control group.The CYP2C9*3 and-1190A/G and-1195G/A gene polymorphisms in the promoter regions of COX-2 genes were observed.The changes of clinical data of AS patients before and after treatment were observed,and the differences of ASAS20 and ASAS40 in AS patients with different genotypes of CYP2C9*3,COX-2-1190A/G and COX-2-1195G/A were observed.Results There was no significant difference in CYP2C9*3 genotype and allele frequency between the two groups(P＞0.05).There was significant difference in COX-2-1290A/G genotype and allele frequency between the two groups(P＜0.05).There was significant difference in COX-2-1195G/A genotype and allele frequency between the two groups(P＜0.05).After treatment,the duration of morning stiffness,peripheral joint involvement,finger ground distance,occipital wall distance,Schober test,ESR,CRP,BASDAI(VAS),BASDAI≥4,BASFI(VAS)and overall evaluation(VAS)of AS patients were significantly lower than those before treatment(P＜0.05).Among the 117 patients,68 patients(58.12％)met the ASAS20 improvement standard and 30 patients(25.64％)met the ASAS40 improvement standard.There was no significant difference in ASAS20 and ASAS40 between different CYP2C9*3 genotypes(A A,AC+CC)(P＞0.05).There was significant difference in ASAS20 and ASAS40 between different COX-2-1290A/G genotypes(P＜0.05).ASAS20 and ASAS40 in patients with AA genotype were higher than those in patients with AG+GG genotype(P＜0.05).There was significant difference in ASAS20 and ASAS40 between different COX-2-1195G/A genotypes(P＜0.05),and the ASAS20 and ASAS40 of GG+AA genotypes were higher than those of GG patients(P＜0.05).Conclusions COX-2-1290A/G and COX-2-1195G/A polymorphisms can increase the risk of AS and may be biological indicators to predict the efficacy of NSAIDs in the treatment of AS.The relationship between CYP2C9*3 polymorphism and the efficacy of non steroidal anti-inflammatory drugs in the treatment of AS needs to be further studied.
维普
万方数据